Get the Stockscreener App
1.06
1.92%
0.02
After Hours:
1.05
-0.01
-0.94%
Therapeuticsmd Inc stock is traded at $1.06, with a volume of 59,654.
It is up +1.92% in the last 24 hours and down -7.02% over the past month.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
See More
Previous Close:
$1.04
Open:
$1.03
24h Volume:
59,654
Relative Volume:
0.22
Market Cap:
$12.22M
Revenue:
$996.00K
Net Income/Loss:
$-6.09M
P/E Ratio:
-2.00
EPS:
-0.53
Net Cash Flow:
$-9.76M
1W Performance:
-3.64%
1M Performance:
-7.02%
6M Performance:
-41.14%
1Y Performance:
-53.51%
1-Day Range:
$1.02
$1.0999
1-Week Range:
$0.9856
$1.1391
52-Week Range:
$0.70
$2.75
Therapeuticsmd Inc Stock (TXMD) Company Profile
Name
Therapeuticsmd Inc
Sector
Phone
561-961-1900
Address
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
Compare TXMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TXMD
Therapeuticsmd Inc
|
1.06 | 12.22M | 996.00K | -6.09M | -9.76M | -0.53 |
|
ZTS
Zoetis Inc
|
165.89 | 74.84B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
12.92 | 40.96B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.92 | 24.83B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
143.26 | 14.50B | 2.24B | 385.90M | 440.10M | 3.73 |
Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-07-20 | Downgrade | Jefferies | Hold → Underperform |
| May-19-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-02-19 | Initiated | Guggenheim | Buy |
| Oct-17-19 | Initiated | H.C. Wainwright | Buy |
| Apr-30-19 | Resumed | Noble Capital Markets | Outperform |
| Jun-15-18 | Initiated | JP Morgan | Overweight |
| Sep-08-17 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-11-17 | Upgrade | Oppenheimer | Perform → Outperform |
| May-09-17 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-22-16 | Resumed | Jefferies | Buy |
| Nov-22-16 | Initiated | Oppenheimer | Outperform |
| Nov-07-16 | Resumed | Guggenheim | Buy |
| Apr-04-16 | Initiated | Goldman | Buy |
| Dec-08-15 | Reiterated | Jefferies | Buy |
| Dec-08-15 | Reiterated | Stifel | Buy |
| Sep-21-15 | Reiterated | Jefferies | Buy |
| Jun-09-15 | Initiated | Guggenheim | Buy |
| Jul-08-14 | Initiated | FBR Capital | Outperform |
| Apr-17-14 | Reiterated | Noble Financial | Buy |
| Jan-28-14 | Reiterated | Noble Financial | Buy |
View All
Therapeuticsmd Inc Stock (TXMD) Latest News
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock outperforms competitors despite losses on the day - MarketWatch
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
TherapeuticsMD (NASDAQ:TXMD) Coverage Initiated at StockNews.com - Defense World
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors - MarketWatch
3 Promising US Penny Stocks With Over $9M Market Cap - Simply Wall St
StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD) - Defense World
TXMD stock touches 52-week low at $1.04 amid market challenges - Investing.com Nigeria
TXMD stock touches 52-week low at $1.04 amid market challenges By Investing.com - Investing.com South Africa
TherapeuticsMD Inc. stock remains steady Friday, still outperforms market - MarketWatch
StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD) - Defense World
TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com - Defense World
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
TXMD stock touches 52-week low at $1.13 amid market challenges By Investing.com - Investing.com South Africa
TXMD stock touches 52-week low at $1.13 amid market challenges - Investing.com India
TherapeuticsMD Inc. stock remains steady Thursday, still outperforms market - MarketWatch
TherapeuticsMD holds annual meeting, elects directors - Investing.com
TherapeuticsMD holds annual meeting, elects directors By Investing.com - Investing.com Canada
TherapeuticsMD (STU:29TA) 3-Year FCF Growth Rate : 57.70% (As of Sep. 2024) - GuruFocus.com
TherapeuticsMD Inc. stock rises Friday, still underperforms market - MarketWatch
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Therapeuticsmd Inc Stock (TXMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):